Biopolym. Cell. 2003; 19(3):262-269.
Viruses and Cell
Usage of new bacterial adjuvants for vaccination by anti-influenza and anti-poliomyelitis vaccines
1Rybalko S. L., 1Khristova M. L., 1Shapiro A. V., 2Varbanets L. D., 1Zubkova N. L., 1Zadorozhna V. I., 3Ivans'ka N. V., 2Sorokulova I. B., 1Grytsak T. F., 1Furzikova T. M., 2Pinchuk I. I., 3Patskovski Yu. V., 1Diadiun S. T., 2Smirnov V. V., 2Urdaci M. A.
  1. Gromashevsky L.V. Institute of Epidemiology and Infection Diseases, AMS of Ukraine
    5, Amosova Str., Kyiv, Ukraine, 03038
  2. D. K. Zabolotny Institute of Microbiology and Virology, NAS of Ukraine
    154, Academika Zabolotnogo Str., Kyiv, Ukraine, 03680
  3. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03680


The authors have compared activities of three bacterial adjuvant-neuraminins isolated from culture fluids of Staphylococcus aureus, Streptococcus pneumoniae and Bacillus subtilis 105 taking into consideration their influence on the immune response following anti-influenza and anti-poliomyelitis vaccination. Bacterial adjuvants stimulate humoral immune response and help to develop more early anti-influenza IgG together with IgM antibodies (on the first week of immunization). This phenomenon may be due to the peptide mimicry of neuraminins and influenza virus hemagglutinins. In an animal model the S. aureus neuraminin is shown to stimulate a more prolonged antibody synthesis against polioviruses types 1 and 3. Due to such mimicry, neuraminins may be used for priming and acceleration of prolonged immune answer following booster immunization. Being non-toxic, neuraminins are promising compounds for the adjuvant therapy.


[1] Edelman R. Vaccine adjuvants. Rev Infect Dis. 1980;2(3):370-83.
[2] Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK. Adjuvants--a balance between toxicity and adjuvanticity. Vaccine. 1993;11(3):293-306.
[3] Schultz N, Oratz R, Chen D, Zeleniuch-Jacquotte A, Abeles G, Bystryn JC. Effect of DETOX as an adjuvant for melanoma vaccine. Vaccine. 1995;13(5):503-8.
[4] Bergquist C, Lagerg?rd T, Holmgren J. Antibody responses in serum and lung to intranasal immunization with Haemophilus influenzae type b polysaccharide conjugated to cholera toxin B subunit and tetanus toxoid . APMIS. 1998;106(7-12):800–6.
[5] Freytag LC, Clements JD. Bacterial toxins as mucosal adjuvants. Curr Top Microbiol Immunol. 1999;236:215-36.
[6] Pouwels PH, Leer RJ, Shaw M, Heijne den Bak-Glashouwer MJ, Tielen FD, Smit E, Martinez B, Jore J, Conway PL. Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes. Int J Food Microbiol. 1998;41(2):155-67.
[7] Verweij WR, de Haan L, Holtrop M, Agsteribbe E, Brands R, van Scharrenburg GJ, Wilschut J. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Vaccine. 1998;16(20):2069-76.
[8] Bessler WG, Huber M, Baier W. Bacterial cell wall components as immunomodulators--II. The bacterial cell wall extract OM-85 BV as unspecific activator, immunogen and adjuvant in mice. Int J Immunopharmacol. 1997;19(9-10):551-8.
[9] Medina E, Talay SR, Chhatwal GS, Guzm?n CA. Fibronectin-binding protein I of Streptococcus pyogenes is a promising adjuvant for antigens delivered by mucosal route. Eur J Immunol. 1998;28(3):1069-77.
[10] AS. N 924949. A method of producing neuraminidase inhibitor. LF Frolov, LV Shapiro, SL Rybalko. Publ. 04.10.1982.
[11] Lin W, Oishi K, Aida K. Viral-neuraminidase inhibitors of microbial origin. III. Isolation, purification, and physical and chemical properties of neuraminidase inhibitor No. 289. Agricultural and Biological Chemistry. 1975;39(5):923–30.
[12] Zubkova NL, Rybalko SL, Zadorozhna VI, Shapiro AV. Study of the neuraminin influence on polioviruses reproduction in cell culture HEp-2. Lab Diagn. 2002; (1):36-8.
[13] Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265-75.
[14] DuBois M, Gilles KA, Hamilton JK, Rebers PA, Smith F. Colorimetric Method for Determination of Sugars and Related Substances. Anal Chem. 1956;28(3):350–6.
[15] Zakharova IYu, Kosenko LV. Methods of microbiological studies of polysaccharide. Kiev: Naukova Dumka, 1982. 189 p.
[16] Voller A, Bidwell DB, Bartlett A. A guide with abstracts of microplate applications. Dynatech Europe: Guernsey. 1979. 183 p.
[17] Guide virological studies polio. Global. prog. vaccinology and immunology at WHO. Geneva; Moscow, 1998; 45 p.
[18] Rybalko SL, Shapiro AV, Sorokulova IB. Antigenic mimicry peptides of bacteria and viruses in the design of vaccines. III International. Conf Morden vaccinology (3-6 May 1998) Kiev, 1998;10.